Primary Objectives -Assess safety and tolerability at increasing dose levels of HPN328 in successive cohorts of patients with solid tumors associated with expression of DLL3 -Estimate the maximum tolerated dose (MTD) or select the recommended Phase 2 dose (RP2D) -Characterize the PK of HPN328 following IV administration Secondary Objectives -Evaluate the preliminary efficacy of HPN328 -Evaluate the immunogenicity of HPN328
What is the full name of this clinical trial?
HPN328-4001: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 Who Have Failed Standard Available Therapy